Расширенный поиск


Полный текст:


В обзоре отражено современное состояние протеомных исследований по поиску и идентификации потенциальных маркеров рака почки. Рассматриваются маркеры, найденные в биологических жидкостях, опухолевой ткани, а также выявленные с использованием моделей клеточных культур рака почки.

Об авторах

С. В. Ковалев
НИИ канцерогенеза РОНЦ им. Н.Н. Блохина РАМН, Москва

В. Е. Шевченко
НИИ канцерогенеза РОНЦ им. Н.Н. Блохина РАМН, Москва

Список литературы

1. Ljungberg B., Cowan N.C., Hanbury D.C. et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398– 406.

2. Заридзе Д.Г. Профилактика рака. М.: ИМА-ПРЕСС, 2009.

3. Banks R.E., Craven R.A., Harnden P. et al. Key Clinical issues in renal cancer: a challenges for proteomics. World J Urol 2007;25:37–56.

4. Nickerson M.L., Jaeger E., Shi Y. et al. Improved identification of von Hippel-Lindau gene alternations in clear cell renal tumors. Clin Cancer Res 2008;14(15):4726–34.




8. Hwa J.S., Park H.J., Jung J.H. et al. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci 2005;20:450–5.

9. Pieper R., Gatlin C.L., McGrath A.M. et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 2004;4(4):1159−74.

10. Lichtenfels R., Dressler S.P., Zobawa M. et al. Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by twodimensional gel electrophoresis. Mol Cell Proteomics 2009;8(12):2827−42.

11. Tolson J., Bogumil R., Brunst E. et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004;84:845–56.

12. Siu K.W., DeSouza L.V., Scorilas A. et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res 2009; 8(8):3797−807.

13. Haffey W.D., Mikhaylova O., Meller J. et al. iTRAQ proteomic identification of pVHL-dependent and -independent targets of Egln1 prolyl hydroxylase knockdown in renal carcinoma cells. Adv Enzyme Regul 2009;49(1):121−32.

14. Lichtenfels R., Kellner R., Atkins D. et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003; 1646(1−2):21−31.

15. Kumar S., Tsai C.J., Nussinov R. Temperature range of thermodynamic stability for the native state of reversible two-state proteins. Biochemistry 2003;42(17):4864−73.

16. Rogers M.A., Clarke P., Noble J. et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003; 63(20):6971−83.

17. Bosso N., Chinello C., Picozzi S.C. et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin Appl 2008;2(7−8):1036−46.

18. Wu D.L., Zhang W.H., Wang W.J. et al. Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern. Technol Cancer Res Treat 2008;7(3):155−60.

19. Sim S.H., Cairns D.A., Perkins D.N. et al. Changes in the urinary proteome postoperatively in renal cancer patients — a reflection of tumour or kidney removal? Proteomics Clin Appl 2009;3(9):1112−22.

20. Omenn G.S., States D.J., Adamski M. et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5(13):3226−45.

21. Hara T., Honda K., Ono M. et al. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol 2005;174(4):1213−7.

22. Rossi L., Martin B.M., Hortin G.L. et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006;6:709–20.

23. Panelli M.C., White R., Foster M. et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004;2:17−30.

24. Sabatino M., Kim-Schulze S., Panelli M.C. et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27(16):2645−52.

25. Vermaat J.S., van der Tweel I., Mehra N. et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 2010;21(7):1472−81.

26. Xu G., Xiang C.Q., Lu Y. et al. SELDITOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons. Technol Cancer Res Treat 2009;8(3):225−30.

27. Teng P.N., Hood B.L., Sun M. et al. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. J Proteome Res 2011;10(3):1333−42.

28. Minamida S., Iwamura M., Kodera Y. et al. 14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem 2011;401(1):245−52.

29. Klade C.S., Voss T., Krystek E. et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1(7):890−8.

30. Kellner R., Lichtenfels R., Atkins D. et al. Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance. Proteomics 2002;2(12):1743−51.

31. Unwin R.D., Harnden P., Pappin D. et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003;3:45–55.

32. Kruger T., Schoor O., Lemmel C. et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 2005;54:826–36.

33. Seliger B., Fedorushchenko A., Brenner W. et al. Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 2007;13(1):27−37.

34. Seliger B., Menig M., Lichtenfels R. et al. Identification of markers for the selection of patients undergoing renal cell carcinomaspecific immunotherapy. Proteomics 2003;3(6):979−90.

35. Craven R.A., Hanrahan S., Totty N. et al. Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006;6(13):3880−93.

36. Szymańska K., Moore L.E., Rothman N. et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett 2010; 293(1):92−8.

37. Nakamura E., Abreu-e-Lima P., Awakura Y. et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 2006;168(2):574−84.

38. Aggelis V., Craven R.A., Peng J. et al. Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labeling of a von Hippel-Lindau transfectant cell line model. Proteomics 2009;9(8):2118−30.

39. Shi T., Dong F., Liou L.S. et al. Differential protein profiling in renal-cell carcinoma. Mol Carcinog 2004;40(1):47−61.

40. Perego R.A., Bianchi C., Corizzato M. et al. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. J Proteome Res 2005;4(5):1503−10.

41. Craven R.A., Stanley A.J., Hanrahan S. et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006;6(9):2853−64.

42. Adam P.J., Terrett J.A., Steers G. et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006;95(3):298−306.

43. Alban A., David S.O., Bjorkesten L. et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3(1):36−44.

44. Sarto C., Marocchi A., Sanchez J.C. et al. Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997; 18(3−4):599−604.

45. Zhuang Z., Huang S., Kowalak J.A. et al. From tissue phenotype to proteotype: sensitive protein identification in microdissected tumor tissue. Int J Oncol 2006;28(1):103−10.

46. Bloom G.C., Eschrich S., Zhou J.X. et al. Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 2007; 120(4):769−75.

47. Poznanović S., Wozny W., Schwall G.P. et al. Differential radioactive proteomic analysis of microdissected renal cell carcinoma tissue by 54 cm isoelectric focusing in serial immobilized pH gradient gels. J Proteome Res 2005;4(6):2117−25.

48. Seliger B., Lichtenfels R., Atkins D. et al. Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 2005;5(10):2631−40.

49. Lichtenfels R., Dressler S.P., Zobawa M. et al. Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by twodimensional gel electrophoresis. Mol Cell Proteomics 2009;8(12):2827−42.

50. Kim D.S., Choi Y.P., Kang S. et al. Panel of candidate biomarkers for renal cell carcinoma. J Proteome Res 2010;9(7):3710−9.

51. Okamura N., Masuda T., Gotoh A. et al. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics 2008;8(15):3194−203.

52. Zimmermann U., Balabanov S., Giebel J. et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett 2004;209(1):111−8.

53. Alchanati I., Nallar S.C., Sun P. et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006; 25(54):7138-7147.

54. Castronovo V., Waltregny D., Kischel P. et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006;5(11):2083−91.

55. Dorai T., Sawczuk I.S., Pastorek J. et al. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005;41(18):2935−47.

56. von Eggeling F., Junker K., Fiedle W. et al. Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 2001;22(14):2898−902.

57. Junker K., Gneist J., Melle C. et al. Identification of protein pattern in kidney cancer using ProteinChip arrays and bioinformatics. Int J Mol Med 2005; 15(2):285−90.

58. Johann D.J. Jr., Wei B.R., Prieto D.A. et al. Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem 2010;82(5):1584−8.

59. Minamida S., Iwamura M., Kodera Y. et al. Profilin 1 overexpression in renal cell carcinoma. Int J Urol 2011;18(1):63−71.

Для цитирования:


For citation:


Просмотров: 428

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)